US 11,883,419 B2
DNA polymerase gamma inhibitor and uses thereof
Meltem Muftuoglu, Atasehir/Istanbul (TR); Batu Erman, Tuzla/Istanbul (TR); and Burak Erman, Sariyer/Istanbul (TR)
Assigned to ACIBADEM MEHMET ALI AYDINLAR UNIVERSITESI, Atasehir/Istanbul (TR); SABANCI UNIVERSITESI, Tuzla/Istanbul (TR); and KOC UNIVERSITESI, Sariyer/Istanbul (TR)
Appl. No. 17/255,572
Filed by ACIBADEM MEHMET ALI AYDINLAR UNIVERSITESI, Atasehir/Istanbul (TR); SABANCI UNIVERSITESI, Tuzla/Istanbul (TR); and KOC UNIVERSITESI, Sariyer/Istanbu (TR)
PCT Filed Jun. 25, 2018, PCT No. PCT/TR2018/050320
§ 371(c)(1), (2) Date Dec. 23, 2020,
PCT Pub. No. WO2020/005171, PCT Pub. Date Jan. 2, 2020.
Prior Publication US 2021/0275548 A1, Sep. 9, 2021
Int. Cl. A61K 31/655 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/655 (2013.01) [A61P 35/00 (2018.01)] 3 Claims
 
1. A method of treatment/prevention of cancer cells which are MLH1 mutant/deficient, comprising the step of providing a pharmaceutical composition comprising therapeutically effective amount of a compound having the formula(II):

OG Complex Work Unit Chemistry
and/or pharmaceutically acceptable salts and/or pharmaceutically acceptable solvates in combination with pharmaceutically acceptable diluent, carrier or excipient thereof to a subject in need thereof.